SGLT2 inhibitors cardioprotective even without diabetes, review confirms

Cardiovascular deaths are reduced with the agents but there's no apparent benefit for all-cause mortality, researchers say

Treatment with SGLT2 inhibitors can help keep patients with heart failure out of hospital and protect against cardiovascular disease, regardless of diabetes status, a new analysis shows.

Although the cardioprotective benefits offered by gliflozins in patients with type 2 diabetes is well established, evidence is still emerging regarding their utility outside of the glycaemic control setting, international researchers say.

In an independent systematic review and meta-analysis, the China and UK-led team used data from